T&R Biofab KRX:246710KOSDAQ

티앤알바이오팹 · Korean news coverage and regulatory filings, organized.

Articles, 24h4
Articles, 7 days11
DART filings, 7 days0
Articles tracked27since Sep 11

In Q2 2026, T&R Biofab reported revenue of ₩9.5bn, up 45.9% year on year, and an operating loss of ₩928m. T&R Biofab (티앤알바이오팹) appeared in 11 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Nov 11 with 6 articles. The most common catalyst was tech & capacity (1). It was most often mentioned alongside 글로벌테크놀로지.

Filing signals 4 quarters of losses Screener

T&R Biofab today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates T&R Biofab stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

T&R Biofab quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩9.5bn+45.9%−₩928m
margin −9.7%
−₩3.8bn
Q1 2026₩8.7bn+46.5%−₩931m
margin −10.7%
−₩1.7bn
Q4 2025 derived₩7.5bn+511.9%−₩2.3bn
margin −30.5%
−₩16.6bn
Q3 2025₩7.0bn+534.1%−₩1.3bn
margin −18.2%
−₩5.7bn
Q2 2025₩6.5bn+380.4%−₩1.9bn
margin −29.3%
−₩4.3bn
Q1 2025₩6.0bn+401.5%−₩3.6bn
margin −60.1%
−₩5.4bn
Q4 2024 derived₩1.2bn–−₩2.6bn
margin −212.6%
₩5.8bn
Q3 2024₩1.1bn+15.1%−₩3.1bn
margin −279.2%
−₩4.8bn

T&R Biofab ranks #2054 of 2,582 Korean listed companies by Q2 2026 operating profit. Q2 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

T&R Biofab top stories 2 weeks, by number of outlets

  1. 1
    T&R Biofab acquires patent for artificial skin technology replicating human skin texture
    2 outlets · 3 articlesFirst report Nov 11 15:31 이데일리
  2. 2
    T&R Biofab participates in Medica 2026...expanding medical device distribution channels
    2 outlets · 2 articlesFirst report Nov 16 08:10 핀포인트뉴스
  3. 3
    T&R Biofab registers patent for 3D bioprinting artificial skin manufacturing technology
    1 outlets · 1 articlesFirst report Nov 11 09:35 히트뉴스New technology
  4. 4
    T&R BiofabPharma pursuing global export expansion based on FDA approval at Germany's Medica 2026
    1 outlets · 1 articlesFirst report Nov 16 09:46 바이오타임즈Regulatory approval글로벌테크놀로지
  5. 5
    T&R Biofab obtains patent for artificial skin manufacturing that replicates actual skin contours
    1 outlets · 1 articlesFirst report Nov 11 11:07 바이오타임즈
  6. 6

Latest T&R Biofab news Korean headlines